MA32025B1 - Inhibiteurs des beta-lactamases - Google Patents

Inhibiteurs des beta-lactamases

Info

Publication number
MA32025B1
MA32025B1 MA33026A MA33026A MA32025B1 MA 32025 B1 MA32025 B1 MA 32025B1 MA 33026 A MA33026 A MA 33026A MA 33026 A MA33026 A MA 33026A MA 32025 B1 MA32025 B1 MA 32025B1
Authority
MA
Morocco
Prior art keywords
beta
lactamase inhibitors
compounds
lactam antibiotics
lactam
Prior art date
Application number
MA33026A
Other languages
Arabic (ar)
English (en)
Inventor
Timothy A Blizzard
Helen Chen
Candido Gude
Jeffrey D Hermes
Jason E Imbriglio
Seongkon Kim
Jane Y Wu
Sookhee Ha
Christopher J Mortko
Ian Mangion
Nelo Rivera
Rebecca T Ruck
Michael Shevlin
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Publication of MA32025B1 publication Critical patent/MA32025B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C07D211/58—Nitrogen atoms attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D211/78—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
  • Pyrrole Compounds (AREA)

Abstract

L'invention concerne des bêta-lactames bicycliques substitués de la formule i : (i), sont des inhibiteurs de b-lactamase, a, x, r1 et r2 étant décrits par les présentes. Les composés et les sels de qualité pharmaceutique de ceux-ci s'utilisent dans le traitement d'infections bactériennes en combinaison avec des antibiotiques de b-lactame. En particulier, les composés peuvent être utilisés avec des antibiotiques de b-lactame (par exemple l'imipenème, la pipéracilline ou la ceftazidime) contre des micro-organismes résistants aux antibiotiques de b-lactame dus à la présence des b-lactamases.
MA33026A 2008-01-18 2010-07-16 Inhibiteurs des beta-lactamases MA32025B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US1153308P 2008-01-18 2008-01-18
PCT/US2009/031047 WO2009091856A2 (fr) 2008-01-18 2009-01-15 Inhibiteurs de bêta-lactamase

Publications (1)

Publication Number Publication Date
MA32025B1 true MA32025B1 (fr) 2011-01-03

Family

ID=40642204

Family Applications (1)

Application Number Title Priority Date Filing Date
MA33026A MA32025B1 (fr) 2008-01-18 2010-07-16 Inhibiteurs des beta-lactamases

Country Status (39)

Country Link
US (2) US8487093B2 (fr)
EP (2) EP2231667B1 (fr)
JP (3) JP5038509B2 (fr)
KR (2) KR101648728B1 (fr)
CN (2) CN101918407B (fr)
AU (1) AU2009206119C1 (fr)
BR (1) BRPI0906871B1 (fr)
CA (1) CA2712783C (fr)
CO (1) CO6331438A2 (fr)
CR (1) CR11626A (fr)
CY (5) CY1114900T1 (fr)
DK (2) DK2231667T3 (fr)
DO (1) DOP2010000218A (fr)
EC (2) ECSP10010345A (fr)
ES (2) ES2433744T3 (fr)
FR (3) FR20C1032I2 (fr)
HK (2) HK1143809A1 (fr)
HN (1) HN2010001395A (fr)
HR (2) HRP20131123T1 (fr)
HU (2) HUS000513I2 (fr)
IL (1) IL206395A (fr)
LT (3) LTC2231667I2 (fr)
LU (1) LUC00165I2 (fr)
MA (1) MA32025B1 (fr)
ME (1) ME02089B (fr)
MX (1) MX2010007823A (fr)
MY (1) MY162532A (fr)
NI (1) NI201000115A (fr)
NL (2) NL301051I2 (fr)
NO (1) NO2020024I1 (fr)
NZ (1) NZ586861A (fr)
PL (2) PL2666774T3 (fr)
PT (2) PT2666774E (fr)
RS (2) RS53862B1 (fr)
RU (1) RU2445314C9 (fr)
SI (2) SI2231667T1 (fr)
UA (1) UA101966C2 (fr)
WO (1) WO2009091856A2 (fr)
ZA (1) ZA201005333B (fr)

Families Citing this family (97)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY162532A (en) * 2008-01-18 2017-06-15 Merck Sharp & Dohme Beta-lactamase inhibitors
RS60310B1 (sr) 2010-08-10 2020-07-31 Rempex Pharmaceuticals Inc Ciklični derivati estra boronske kiseline, postupak za pripremu injihove terapeutske upotrebe
US8772490B2 (en) * 2010-12-22 2014-07-08 Meiji Seika Pharma Co., Ltd. Optically active diazabicyclooctane derivatives and process for preparing the same
CA2822758C (fr) 2010-12-22 2018-03-20 Meiji Seika Pharma Co., Ltd. Derive de diazabicyclooctane optiquement actif et son procede de preparation
JP6023800B2 (ja) * 2011-06-17 2016-11-09 アストラゼネカ アクチボラグ ｔｒａｎｓ−７−オキソ−６−（スルホオキシ）−１，６−ジアザビシクロ［３，２，１］オクタン−２−カルボキサミドとその塩が含まれる複素環式化合物を製造するための方法
MX348974B (es) * 2011-08-27 2017-07-04 Wockhardt Ltd Derivados 1,6 - diazabiciclo [3,2,1] octan-7-ona y su uso en el tratamiento de infecciones bacterianas.
EP2872510B1 (fr) 2011-08-30 2016-11-23 Wockhardt Limited Dérivés 1,6-diazabicyclo[3,2,1]octane-7-one et leur utilisation dans le traitent d'infections bactériennes
US9012491B2 (en) 2011-08-31 2015-04-21 Rempex Pharmaceuticals, Inc. Heterocyclic boronic acid ester derivatives and therapeutic uses thereof
US8796257B2 (en) 2011-12-02 2014-08-05 Naeja Pharmaceutical Inc. Bicyclic compounds and their use as antibacterial agents and β-lactamase inhibitors
US9505761B2 (en) 2011-12-02 2016-11-29 Fedora Pharmaceuticals Inc. Bicyclic compounds and their use as antibacterial agents and beta-lactamase inhibitors
CA2860672A1 (fr) * 2012-01-06 2013-07-11 University Of South Florida Compositions, procedes d'utilisation et procedes de traitement
WO2013149121A1 (fr) 2012-03-30 2013-10-03 Cubist Pharmaceuticals, Inc. Inhibiteurs de la 1,3,4-oxadiazole et de la 1,3,4-thiadiazole bêta-lactamase
US8916709B2 (en) 2012-03-30 2014-12-23 Cubist Pharmaceuticals, Inc. 1,2,4-oxadiazole and 1,2,4-thiadiazole β-lactamase inhibitors
US8927724B2 (en) * 2012-03-30 2015-01-06 Cubist Pharmaceuticals, Inc. Isoxazole beta-lactamase inhibitors
US8969570B2 (en) * 2012-03-30 2015-03-03 Cubist Pharmaceuticals, Inc. Beta-lactamase inhibitors
AR090539A1 (es) 2012-04-02 2014-11-19 Astrazeneca Ab COMPUESTOS INHIBIDORES DE b LACTAMASA
EP2847327B1 (fr) 2012-05-08 2018-12-26 Codexis, Inc. Biocatalyseurs et procédés pour l'hydroxylation de composés chimiques
US9156858B2 (en) 2012-05-23 2015-10-13 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
MX366948B (es) 2012-05-30 2019-07-30 Meiji Seika Pharma Co Ltd Nuevo inhibidor de beta-lactamasa y proceso para prepararlo.
US10561675B2 (en) 2012-06-06 2020-02-18 Rempex Pharmaceuticals, Inc. Cyclic boronic acid ester derivatives and therapeutic uses thereof
BR112015003592B1 (pt) * 2012-08-25 2020-04-14 Wockhardt Ltd derivados de 1,6-diazabiciclo[3,2,1]octan-7-ona e seu uso no tratamento de infecções bacterianas
US20150315145A1 (en) * 2012-11-01 2015-11-05 Kaneka Corporation Process for producing optically active bicyclic urea compound
EP2928898B1 (fr) 2012-12-07 2021-04-14 Venatorx Pharmaceuticals, Inc. Inhibiteurs de bêta-lactamase
UA111925C2 (uk) 2012-12-11 2016-06-24 Федора Фармасьютікалз Інк. БІЦИКЛІЧНІ СПОЛУКИ ТА ЇХ ВИКОРИСТАННЯ ЯК АНТИБАКТЕРІАЛЬНИХ АГЕНТІВ ТА ІНГІБІТОРІВ β-ЛАКТАМАЗИ
EA201591004A1 (ru) 2013-01-04 2016-02-29 Ремпекс Фармасьютикалз, Инк. Производные бороновой кислоты и их терапевтическое применение
US9241947B2 (en) 2013-01-04 2016-01-26 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
CA2894891A1 (fr) 2013-01-04 2014-07-10 Rempex Pharmaceuticals, Inc. Derives d'acide boronique et leurs utilisations therapeutiques
US9101638B2 (en) 2013-01-04 2015-08-11 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
ES2730013T3 (es) 2013-01-10 2019-11-07 Venatorx Pharmaceuticals Inc Inhibidores de betalactamasa
NZ711328A (en) 2013-03-08 2016-06-24 Wockhardt Ltd A process for preparation of (2s, 5r)-7-oxo-6-sulphooxy-2-[((3r)-pyrrolidine-3-carbonyl)-hydrazino carbonyl]-1,6-diaza-bicyclo[3.2.1]octane
JP6285969B2 (ja) * 2013-03-08 2018-02-28 ウォックハート リミテッド （２ｓ，５ｒ）−７−オキソ−６−スルホオキシ−２−［（（３ｒ）−ピペリジン−３−カルボニル）−ヒドラジノカルボニル］−１，６−ジアザ−ビシクロ［３．２．１］オクタンの調製のためのプロセス
KR101774132B1 (ko) 2013-03-08 2017-09-01 욱크하르트 리미티드 (2s, 5r)-7-옥소-6-술포옥시-2-[((3r)-피페리딘-3-카보닐)-히드라지노 카보닐]-1,6-디아자-비사이클로[3.2.1]-옥탄의 제조 방법
WO2014135931A1 (fr) * 2013-03-08 2014-09-12 Wockhardt Limited Procédé pour la préparation du (2s, 5r)-7-oxo-6-sulfo-oxy-2-[((3r)-pipéridine-3-carbonyl)-hydrazino carbonyl]-1,6-diaza-bicyclo[3.2.1]octane
CA2904084C (fr) * 2013-03-08 2017-03-28 Wockhardt Limited Procede de preparation de (2s, 5r)- acide sulfurique mono-{[(4- aminopiperidin-4-yl) carbonyl]-7-oxo-1,6-diaza-bicyclo[3.2.1]-oct-6-yl} ester
EP3013829A1 (fr) 2013-03-08 2016-05-04 Wockhardt Limited Procédé pour sel de sodium de (2s, 5r)-2-carboxamido -7-oxo-6-sulfooxy -1,6-diaza-bicyclo[3.2.1]octane
EP2970338A1 (fr) * 2013-03-14 2016-01-20 Merck Sharp & Dohme Corp. Forme cristalline d'un inhibiteur de bêta-lactamase
EP2970340B1 (fr) 2013-03-14 2020-02-12 Venatorx Pharmaceuticals, Inc. Inhibiteurs de bêta-lactamase
US9604985B2 (en) 2013-06-10 2017-03-28 Merck Sharp & Dohme Corp. Process for the preparation of chiral tert-butyl 4-((1R,2S,5R)-6(benzyloxy)-7-oxo-1,6-diazabicyclo[3.2.1]octane-2-carboxamido)piperidine-1-carb derivatives and (2S,5R)-7-oxo-N-piperidin-4-yl-6-(sulfoxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide
CN105555787B (zh) 2013-09-24 2017-08-08 明治制果药业株式会社 二氮杂二环辛烷衍生物的制备方法及其中间体
US9120796B2 (en) 2013-10-02 2015-09-01 Cubist Pharmaceuticals, Inc. B-lactamase inhibitor picoline salt
AR097971A1 (es) * 2013-10-08 2016-04-20 Meiji Seika Pharma Co Ltd Formas cristalinas de derivado de diazabiciclooctano y proceso de producción de ellas
WO2015079329A2 (fr) * 2013-11-26 2015-06-04 Wockhardt Limited Procédé de préparation de (2s, 5r)-7-oxo-n-[(2s)-pyrrolidin-2-yl-méthyloxy]-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide
MA39777B1 (fr) 2014-03-24 2019-03-29 Novartis Ag Composes organiques de la famille des monobactams pour le traitement d'infections bactériennes
WO2015150891A1 (fr) * 2014-03-29 2015-10-08 Wockhardt Limited Procédé de préparation de mono-[2-(5-azétidin-3-ylméthyl-[1,3,4]oxadiazol-2-yl)-7-oxo-1,6-diazabicyclo[3.2.1]oct-6-yl]ester d'acide sulfurique trans
WO2015150890A1 (fr) * 2014-03-29 2015-10-08 Wockhardt Limited Procédé de préparation de mono-{2-(5-(3-amino-propyl)-[1,3,4]oxadiazol-2-yl]-7-oxo-1,6-diazabicyclo[3.2.1]oct-6-yl}ester d'acide sulfurique trans
WO2015171398A1 (fr) 2014-05-05 2015-11-12 Rempex Pharmaceuticals, Inc. Sels et polymorphes de dérivés cycliques d'ester d'acide boronique, et leurs utilisations thérapeutiques
US10385074B2 (en) 2014-05-05 2019-08-20 Rempex Pharmaceuticals, Inc. Synthesis of boronate salts and uses thereof
CA2947041A1 (fr) 2014-05-19 2015-11-26 Rempex Pharmaceuticals, Inc. Derives d'acide boronique et leurs utilisations therapeutiques
EP3154989B1 (fr) 2014-06-11 2021-03-24 Venatorx Pharmaceuticals, Inc. Inhibiteurs de bêta-lactamases
US9511142B2 (en) 2014-06-11 2016-12-06 VenatoRx Pharmaceuticals, Inc. Beta-lactamase inhibitors
EA201692301A1 (ru) 2014-07-01 2017-06-30 Ремпекс Фармасьютикалз, Инк. Производные бороновой кислоты и их терапевтическое применение
SI3221313T1 (sl) 2014-11-17 2019-04-30 Entasis Therapeutics Limited Kombinacijska terapija za zdravljenje okužb z rezistentnimi bakterijami
WO2016081297A1 (fr) 2014-11-18 2016-05-26 Rempex Pharmaceuticals, Inc. Dérivés d'esters d'acide boronique cycliques et leurs utilisations thérapeutiques
WO2016089718A1 (fr) 2014-12-02 2016-06-09 Merck Sharp & Dohme Corp. Procédé pour la préparation de 4-((2s,5r)-6-(benzyloxy)-7-oxo-1,6-diazabicyclo[3.2.1]octane-2-carboxamido)-pipéridine-1-carboxylate de tert-butyle et ses analogues
TWI691499B (zh) 2014-12-05 2020-04-21 日商明治製菓藥業股份有限公司 二氮雜雙環辛烷衍生物之結晶及安定的凍結乾燥製劑的製造法
US20180051041A1 (en) 2015-03-17 2018-02-22 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
WO2016156346A1 (fr) 2015-03-31 2016-10-06 Mutabilis Composés hétérocycliques et leur utilisation dans la prévention ou le traitement d'infections bactériennes
AU2016257338B2 (en) * 2015-05-07 2020-03-05 Mutabilis Heterocyclic compounds and their use in preventing or treating bacterial infections
CN108472284A (zh) 2015-09-11 2018-08-31 维纳拓尔斯制药公司 β-内酰胺酶抑制剂
WO2017045510A1 (fr) * 2015-09-16 2017-03-23 山东轩竹医药科技有限公司 Inhibiteur de ss-lactamase et son application
JP2018530553A (ja) 2015-10-02 2018-10-18 レゴケム バイオサイエンシズ， インク．Ｌｅｇｏｃｈｅｍ Ｂｉｏｓｃｉｅｎｃｅｓ， Ｉｎｃ． β−ラクタマーゼを阻害するための組成物及び方法
WO2017100537A1 (fr) 2015-12-10 2017-06-15 VenatoRx Pharmaceuticals, Inc. Inhibiteurs de bêta-lactamases
US10501464B2 (en) * 2015-12-11 2019-12-10 Wockhardt Limited 7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide containing compounds and their use in treating bacterial infections
EP3411359B1 (fr) 2016-02-04 2021-10-13 Merck Sharp & Dohme Corp. Procédés de préparation de dérivés d'hydroxylamine utiles dans la préparation d'agents anti-infectieux
WO2017167218A1 (fr) * 2016-03-31 2017-10-05 山东轩竹医药科技有限公司 Composition antibactérienne et son utilisation
EP3469088B1 (fr) 2016-06-09 2023-09-06 Codexis, Inc. Biocatalyseurs et procédés d'hydroxylation de composés chimiques
MY196909A (en) 2016-06-30 2023-05-09 Qpex Biopharma Inc Boronic acid derivatives and therapeutic uses thereof
WO2018027062A1 (fr) 2016-08-04 2018-02-08 VenatoRx Pharmaceuticals, Inc. Composés contenant du bore
SG11201901658PA (en) * 2016-09-16 2019-04-29 Entasis Therapeutics Ltd Beta-lactamase inhibitor compounds
WO2018053057A2 (fr) * 2016-09-19 2018-03-22 Merck Sharp & Dohme Corp. Procédé de préparation d'intermédiaires d'hydroxyurée inhibiteurs des bêta-lactamases
JOP20190061A1 (ar) 2016-09-28 2019-03-26 Novartis Ag مثبطات بيتا-لاكتاماز
CN108078982B (zh) * 2016-11-21 2020-02-07 天津大学 脯氨酸衍生物在制备β-内酰胺酶抑制剂中的用途
KR102603489B1 (ko) 2017-03-06 2023-11-16 에버레스트 메디신즈 (싱가포르) 피티이. 리미티드 베타-락타마제 억제제를 포함하는 고체 형태 및 조합 조성물과 이의 용도
CN108619141B (zh) * 2017-03-16 2021-09-10 山东轩竹医药科技有限公司 一种抗菌组合物及其用途
DK3630111T3 (en) 2017-05-08 2022-03-14 Entasis Therapeutics Inc Compounds and methods for treating bacterial infections
US10085999B1 (en) 2017-05-10 2018-10-02 Arixa Pharmaceuticals, Inc. Beta-lactamase inhibitors and uses thereof
US11267826B2 (en) 2017-05-26 2022-03-08 VenatoRx Pharmaceuticals, Inc. Penicillin-binding protein inhibitors
WO2018218190A1 (fr) 2017-05-26 2018-11-29 VenatoRx Pharmaceuticals, Inc. Inhibiteurs de protéines de liaison à la pénicilline
JP2020528412A (ja) 2017-07-21 2020-09-24 アンタビオ エスアーエス 化学的化合物
CN109568323B (zh) * 2017-09-29 2022-09-30 吉林四环制药有限公司 抗菌组合物及其用途
CA3078627A1 (fr) 2017-10-11 2019-04-18 Qpex Biopharma, Inc. Derives d'acide boronique et synthese de ces derniers
JP6974614B2 (ja) 2017-12-01 2021-12-01 チールー ファーマシューティカル カンパニー、リミテッド β−ラクタマーゼ阻害剤の結晶形およびその製造方法
CN109956941B (zh) * 2017-12-25 2020-08-04 新发药业有限公司 一种阿维巴坦的简便制备方法
CA3089150A1 (fr) * 2018-01-25 2019-01-24 Suzhou Sinovent Pharmaceuticals Co., Ltd. Nhibiteurs de beta-lactamase et leur utilisation
EP3572411A1 (fr) 2018-05-21 2019-11-27 Antabio SAS Dérivés de thiazole comme inhibiteurs de métallo-bêta-lactamases
TWI764030B (zh) * 2018-08-09 2022-05-11 法商安塔比奧公司 化合物
US11905286B2 (en) 2018-08-09 2024-02-20 Antabio Sas Diazabicyclooctanones as inhibitors of serine beta-lactamases
EP3670512A1 (fr) * 2018-12-18 2020-06-24 Antabio SAS Diazabicyclooctanones comme inhibiteurs de sérine beta-lactamases
JPWO2020059891A1 (ja) * 2018-09-21 2021-08-30 株式会社エーピーアイ コーポレーション アミノ酸誘導体の製造方法
JP7437847B2 (ja) * 2018-10-01 2024-02-26 アリクサ ファーマシューティカルズ、インコーポレイテッド レレバクタムの誘導体およびその使用
CN111072660B (zh) * 2018-10-22 2021-05-18 新发药业有限公司 一种瑞来巴坦的简便制备方法
CN113614084A (zh) 2019-03-12 2021-11-05 阿里萨制药公司 阿维巴坦衍生物的晶型
CN114206851A (zh) * 2019-04-26 2022-03-18 默沙东公司 可用于制备(2s,5r)-7-氧代-n-哌啶-4-基-6-(硫酸基)-1,6-二氮杂双环[3.2.1]辛烷-2-甲酰胺的中间体的制备方法
WO2022047790A1 (fr) * 2020-09-07 2022-03-10 Ningxia Academy Of Agriculture And Forestry Sciences Composés bicycliques substitués par amidine, leur préparation, leur utilisation comme agents antibactériens et inhibiteurs de bêta-lactamase
CN111943950B (zh) * 2020-09-10 2022-03-29 山东安信制药有限公司 一种瑞来巴坦的制备方法
US11814385B2 (en) * 2021-06-25 2023-11-14 University Of South Florida Small molecule inhibitors targeting Clostridioides difficile sporulation
WO2023220324A1 (fr) * 2022-05-11 2023-11-16 The Regents Of The University Of Colorado A Body Corporate Composition antibiotique et ses procédés d'utilisation

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4616038A (en) 1978-07-24 1986-10-07 Merck & Co., Inc. Combination of thienamycin-type antibiotics with dipeptidase inhibitors
US4880793A (en) 1978-07-24 1989-11-14 Merck & Co., Inc. Combination of thienamycin-type antibiotics with dipeptidase inhibitors
US5071843A (en) 1978-07-24 1991-12-10 Merck & Co., Inc. Combination of 2-substituted carbapenems with dipeptidase inhibitors
US4539208A (en) 1980-09-17 1985-09-03 Merck & Co., Inc. Combination of thienamycin-type antibiotics with dipeptidase inhibitors
ES2090393T3 (es) 1991-04-11 1996-10-16 Hoffmann La Roche Beta-lactamas.
BR9408450A (pt) 1993-12-29 1997-08-05 Pfizer Antagonistas da neuroquinina diazabiciclicos
JP3199300B2 (ja) 1994-05-09 2001-08-13 三共株式会社 １−メチルカルバペネム誘導体
HUP9901376A3 (en) 1995-12-21 2000-03-28 Sankyo Company Ltd Chuo Ku 1-methylcarbapenem derivatives, their use, production thereof and medicaments containing the same
JP2965922B2 (ja) * 1995-12-21 1999-10-18 三共株式会社 １−メチルカルバペネム誘導体
JP2955276B2 (ja) 1997-06-19 1999-10-04 三共株式会社 １−メチルカルバペネム誘導体を含有する抗菌剤
JP4490517B2 (ja) 1998-03-19 2010-06-30 富山化学工業株式会社 ５−デオキシ−５−アルカノイルアミノ−β−Ｄ−アロフラノシルウロン酸誘導体またはその塩、それらを含有する抗真菌剤及びキチン合成酵素阻害剤
DE60024455T2 (de) 1999-07-06 2006-08-03 Methylgene, Inc., Saint-Laurent Sulfonamidomethylphosphonat-BETA-LACTAMASE-Inhibitoren
HUP0202514A3 (en) * 1999-08-10 2004-04-28 Vernalis Oxford Ltd Cowley Antibacterial agents
FR2812635B1 (fr) * 2000-08-01 2002-10-11 Aventis Pharma Sa Nouveaux composes heterocycliques, preparation et utilisation comme medicaments notamment comme anti- bacteriens
JP2002212182A (ja) * 2000-11-16 2002-07-31 Sankyo Co Ltd １−メチルカルバペネム誘導体
AU2002215212B2 (en) 2000-11-16 2004-10-14 Sankyo Company, Limited 1-methylcarbapenem derivatives
FR2825705B1 (fr) 2001-06-08 2005-05-20 Aventis Pharma Sa Nouveaux composes heterocycliques, leur preparation et leur utilisation comme medicaments, notamment comme anti-bacteriens
FR2835186B1 (fr) * 2002-01-28 2006-10-20 Aventis Pharma Sa Nouveaux composes heterocycliques, actifs comme inhibiteurs de beta-lactamases
JP2004043438A (ja) 2002-05-15 2004-02-12 Sankyo Co Ltd １−メチルカルバペネム誘導体を含有する医薬
US7439253B2 (en) 2002-12-06 2008-10-21 Novexel Heterocyclic compounds, their preparation and their use as medicaments, in particular as antibacterials and beta-lactamase inhibitors
AU2004259659B2 (en) 2003-07-09 2011-11-03 Paratek Pharmaceuticals, Inc. Substituted tetracycline compounds
US6984652B2 (en) 2003-09-05 2006-01-10 Warner-Lambert Company Llc Gyrase inhibitors
JP2008502583A (ja) 2003-10-01 2008-01-31 バイエル・ヘルスケア・アクチェンゲゼルシャフト 抗細菌性アミド大員環
EP1751527A2 (fr) 2004-02-24 2007-02-14 SSCI, Inc. Analyse et criblage de formes solides au moyen de la fonction de distribution de paires atomiques
KR101403164B1 (ko) * 2005-12-07 2014-06-03 바실리어 파마슈티카 아게 베타-락타마아제 저해제 및 모노박탐 항생물질의 유용한조합
EP2069347A2 (fr) 2006-09-27 2009-06-17 Merck & Co., Inc. Nouveaux inhibiteurs de bêta-lactamase
MY162532A (en) * 2008-01-18 2017-06-15 Merck Sharp & Dohme Beta-lactamase inhibitors

Also Published As

Publication number Publication date
UA101966C2 (en) 2013-05-27
ZA201005333B (en) 2011-04-28
IL206395A0 (en) 2010-12-30
HUS2000023I1 (hu) 2021-03-29
CO6331438A2 (es) 2011-10-20
HRP20131123T1 (hr) 2013-12-20
US8487093B2 (en) 2013-07-16
JP2011207900A (ja) 2011-10-20
CY2020024I1 (el) 2020-11-25
FR20C1031I2 (fr) 2022-07-29
JP5597164B2 (ja) 2014-10-01
WO2009091856A2 (fr) 2009-07-23
KR101800610B1 (ko) 2017-11-23
EP2666774B1 (fr) 2015-01-07
CY2020025I2 (el) 2020-11-25
EP2231667B1 (fr) 2013-09-04
PT2666774E (pt) 2015-04-13
HRP20150269T1 (hr) 2015-04-24
PL2231667T3 (pl) 2014-01-31
RU2445314C9 (ru) 2013-04-10
FR20C1032I2 (fr) 2022-07-29
US20110294777A1 (en) 2011-12-01
LTC2231667I2 (lt) 2021-07-26
MY162532A (en) 2017-06-15
FR20C1032I1 (fr) 2020-02-10
LUC00165I2 (fr) 2021-08-16
DK2666774T3 (en) 2015-03-23
CY2020023I1 (el) 2020-11-25
DOP2010000218A (es) 2010-08-31
CY1116243T1 (el) 2017-03-15
HK1143809A1 (en) 2011-01-14
FR20C1030I1 (fr) 2020-02-10
CN101918407B (zh) 2014-02-26
LTPA2020518I1 (lt) 2020-07-27
HUS2000024I1 (hu) 2021-03-29
JP2012214475A (ja) 2012-11-08
ECSP10010568A (es) 2010-11-30
HK1186180A1 (en) 2014-03-07
CY2020024I2 (el) 2020-11-25
FR20C1030I2 (fr) 2021-08-27
LTPA2020516I1 (lt) 2020-07-27
HUS000513I2 (hu) 2021-03-29
NZ586861A (en) 2011-12-22
BRPI0906871A2 (pt) 2020-07-28
BRPI0906871B1 (pt) 2021-09-28
JP2011510012A (ja) 2011-03-31
LTC2666774I2 (lt) 2022-01-25
HUS000504I2 (hu) 2021-03-29
SI2231667T1 (sl) 2013-12-31
CR11626A (es) 2010-09-13
JP5038509B2 (ja) 2012-10-03
MX2010007823A (es) 2010-08-10
SI2666774T1 (sl) 2015-04-30
CY1114900T1 (el) 2016-12-14
NI201000115A (es) 2011-07-08
AU2009206119C1 (en) 2016-05-26
CA2712783C (fr) 2013-03-19
EP2666774A1 (fr) 2013-11-27
AU2009206119B2 (en) 2012-06-07
CN102827067A (zh) 2012-12-19
NO2020024I1 (no) 2020-08-10
RS53052B (en) 2014-04-30
ME02089B (fr) 2014-04-30
HN2010001395A (es) 2012-11-12
JP5422020B2 (ja) 2014-02-19
RU2445314C1 (ru) 2012-03-20
US20130274475A1 (en) 2013-10-17
AU2009206119A1 (en) 2009-07-23
CA2712783A1 (fr) 2009-07-23
EP2231667A2 (fr) 2010-09-29
PL2666774T3 (pl) 2015-06-30
NL301051I2 (nl) 2020-09-03
CN102827067B (zh) 2015-09-23
CN101918407A (zh) 2010-12-15
CY2020023I2 (el) 2020-11-25
KR101648728B1 (ko) 2016-08-17
CY2020025I1 (el) 2020-11-25
ES2533826T3 (es) 2015-04-15
ES2433744T3 (es) 2013-12-12
IL206395A (en) 2015-04-30
PT2231667E (pt) 2013-12-13
DK2231667T3 (da) 2013-12-16
ECSP10010345A (es) 2010-08-31
KR20100130176A (ko) 2010-12-10
LTPA2020517I1 (lt) 2020-07-27
RS53862B1 (en) 2015-08-31
NL301050I2 (nl) 2020-09-03
KR20160099117A (ko) 2016-08-19
FR20C1031I1 (fr) 2020-02-10
WO2009091856A3 (fr) 2009-12-03

Similar Documents

Publication Publication Date Title
MA32025B1 (fr) Inhibiteurs des beta-lactamases
WO2008039420A3 (fr) Nouveaux inhibiteurs de bêta-lactamase
MA37383A1 (fr) Compose heterobicycliques comme inhibiteurs de la beta lactamase
Issakhanian et al. Antimicrobial agents and urinary tract infections
Aswapokee et al. A sulfone β-lactam compound which acts as a β-lactamase inhibitor
NZ600134A (en) Methylsulfonylmethane (msm) for treatment of drug resistant microorganisms
EA201890150A1 (ru) 3-тетразолил-бензол-1,2-дисульфонамидные производные в качестве ингибиторов металло-бета-лактамазы
PL404913A1 (pl) Zwiazek 2,3-dihydro-6-nitroimidazo[2,1-b]oksazolowy
TW200716102A (en) Bicyclic 6-alkylidene-penems as class-D β -lactamases inhibitors
WO2007004028A3 (fr) Procedes de preparation de penemes et de leurs intermediaires
MX2021001564A (es) Diazabiciclooctanonas como inhibidores de serina beta-lactamasas.
Paterson et al. Fatal infection due to extended-spectrum beta-lactamase-producing Escherichia coli: implications for antibiotic choice for spontaneous bacterial peritonitis.
WO2003020732A3 (fr) 7-alkylidene-3-substitues-3-cephem-4-carboxylates utilises en tant qu'inhibiteurs de $g(b)-lactamase
Majewski et al. Syntheses and biological evaluations of highly functionalized hydroxamate containing and N-methylthio monobactams as anti-tuberculosis and β-lactamase inhibitory agents
TW200727897A (en) Bicyclic 6-alkylidene-penem β-lactamase inhibitors and β-lactam antibiotic combination: a broad spectrum antibiotic
WO2008073142A3 (fr) Nouveaux inhibiteurs de la beta-lactamase
US20100029604A1 (en) Antibacterial combination and its use
US20110172200A1 (en) Use of inhibitor of beta-lactamases and its combination with beta-lactam antibiotics
Ray et al. Imipenem-resistance among multi-drug resistant clinical strains in urinary infections from Kolkata
TW200738235A (en) Tricyclic 6-alkylidene-penem β-lactamase inhibitors and β-lactam antibiotic combination: a broad spectrum antibiotic
WO2007139729A8 (fr) Nouveaux inhibiteurs de bêta-lactamases de type sulfonamidométhylphosphonate
Thirunavukkarasu et al. Clinical evaluation of ceftriaxone and tazobactam in canine urinary tract infection
EA202191461A1 (ru) Комбинированные композиции, содержащие ингибитор -лактамазы, и пути их применения
Santanirand et al. Antimicrobial activity of flomoxef against enterobacteriaceae including extended spectrum beta-lactamases-producing strains isolated at Ramathibodi hospital: A 1000-bed tertiary care hospital in Bangkok, Thailand
MA53270B1 (fr) Diazabicyclooctanones comme inhibiteurs de sérine beta-lactamases